Zaltidine
Modify Date: 2024-01-02 17:35:31
Zaltidine structure
|
Common Name | Zaltidine | ||
|---|---|---|---|---|
| CAS Number | 85604-00-8 | Molecular Weight | 222.27000 | |
| Density | 1.7g/cm3 | Boiling Point | 622.9ºC at 760 mmHg | |
| Molecular Formula | C8H10N6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 330.5ºC | |
Use of ZaltidineZaltidine(CP-57361) is a H2-receptor antagonist, which has the antisecretory action.IC50 Value: Target: H2 receptorin vitro:in vivo: In eight healthy male volunteers single oral doses of 5 mg, 25 mg and 100 mg produced dose-related inhibition of basal and pentagastrin-stimulated acid output (M.A.O.) with an estimated ID50 of 40 mg for the latter. In eight subjects with duodenal ulceration single 100 mg and 200 mg doses produced 85% and 97% inhibition of M.A.O. at peak (3 h post-dose) and 20% and 23% inhibition at 24 h, respectively; inhibition of basal acid output was 97% at 3 h and 50% at 24 h with both doses [1]. One hundred and thirty-five patients were randomly allocated to 4 weeks' treatment with either 150 mg zaltidine once daily or placebo. Fifty-nine were treated for a full 4 weeks with zaltidine before the trial was stopped. Healing rates after 4 weeks of zaltidine and placebo were 86% and 19%, respectively (p less than 0.001) [2]. |
| Name | 2-[4-(2-methyl-1H-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine |
|---|---|
| Synonym | More Synonyms |
| Description | Zaltidine(CP-57361) is a H2-receptor antagonist, which has the antisecretory action.IC50 Value: Target: H2 receptorin vitro:in vivo: In eight healthy male volunteers single oral doses of 5 mg, 25 mg and 100 mg produced dose-related inhibition of basal and pentagastrin-stimulated acid output (M.A.O.) with an estimated ID50 of 40 mg for the latter. In eight subjects with duodenal ulceration single 100 mg and 200 mg doses produced 85% and 97% inhibition of M.A.O. at peak (3 h post-dose) and 20% and 23% inhibition at 24 h, respectively; inhibition of basal acid output was 97% at 3 h and 50% at 24 h with both doses [1]. One hundred and thirty-five patients were randomly allocated to 4 weeks' treatment with either 150 mg zaltidine once daily or placebo. Fifty-nine were treated for a full 4 weeks with zaltidine before the trial was stopped. Healing rates after 4 weeks of zaltidine and placebo were 86% and 19%, respectively (p less than 0.001) [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.7g/cm3 |
|---|---|
| Boiling Point | 622.9ºC at 760 mmHg |
| Molecular Formula | C8H10N6S |
| Molecular Weight | 222.27000 |
| Flash Point | 330.5ºC |
| Exact Mass | 222.06900 |
| PSA | 134.21000 |
| LogP | 2.14710 |
| Index of Refraction | 1.844 |
| Storage condition | 2-8℃ |
| Zaltidine hydrochloride [USAN] |
| Zaltidinum |
| Zaltidina |
| Zaltidine |
| Zaltidine HCl |
| Zaltidinum [Latin] |
| Zaltidina [Spanish] |
| ZALTIDINE HYDROCHLORIDE |